As of November 6, 2026, scPharmaceuticals Inc. has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 8 filings are on record since July 21, 2025 (Schedule 13G/A, February 11, 2026).
Sell to companies like scPharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Weiss Asset Management LP · Percent: 0% · SCHEDULE 13G/A
- · Holder: Lytton Laurence W · Percent: 0% · SCHEDULE 13G/A
- · Holder: Weiss Asset Management LP · Percent: 5.4% · SCHEDULE 13G
- · Holder: Orin Hirschman · Percent: 0% · SCHEDULE 13G/A
- · Holder: Tudor Investment Corporation · Percent: 0% · SCHEDULE 13G
scPharmaceuticals Inc. has 8 Schedule 13D or 13G filings on record since 2025-07-21. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Glazer Capital, LLC | 4.64% | 2,474,820 | SCHEDULE 13G, 2025-09-10 | 2025-09-02 |
| Luther King Capital Management Corporation | 4% | 2,128,391 | SCHEDULE 13G/A, 2025-10-08 | 2025-09-30 |
| Tudor Investment Corporation | 0% | 0 | SCHEDULE 13G, 2025-10-14 | 2025-10-06 |
| 0% | 0 | SCHEDULE 13G/A, 2025-11-10 | 2025-09-30 | |
| Weiss Asset Management LP | 0% | 0 | SCHEDULE 13G/A, 2026-02-11 | 2025-12-31 |
| 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind scPharmaceuticals Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on scPharmaceuticals Inc. and the records around it.
scPharmaceuticals Inc. elsewhere on the record
- Acquisition Oct 2025
Companies that share a holder
- Luther King Capital Management Corporation also filed stake reports on 1 other company: Distribution Solutions Group, Inc. (Sep 2026)
- Tudor Investment Corporation also filed stake reports on 2 other companies: Three Lions Acquisition Corp. (Sep 2026)
- Weiss Asset Management LP also filed stake reports on 9 other companies: Theravance Biopharma, Inc. (Sep 2026), RE/MAX Holdings, Inc. (Aug 2026), Canaan Inc. (Aug 2026)
Watch scPharmaceuticals Inc.
Get an email when scPharmaceuticals Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on scPharmaceuticals Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on scPharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on scPharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-21 | J. Luther King, Jr. | 7% | SCHEDULE 13G/A |
| 2025-09-10 | Glazer Capital, LLC | 4.64% | SCHEDULE 13G |
| 2025-10-08 | Luther King Capital Management Corporation | 4% | SCHEDULE 13G/A |
| 2025-10-14 | Tudor Investment Corporation | 0% | SCHEDULE 13G |
| 2025-11-10 | Orin Hirschman | 0% | SCHEDULE 13G/A |
| 2025-11-12 | Weiss Asset Management LP | 5.4% | SCHEDULE 13G |
| 2025-11-14 | Lytton Laurence W | 0% | SCHEDULE 13G/A |
| 2026-02-11 | Weiss Asset Management LP | 0% | SCHEDULE 13G/A |
Also on the record for scPharmaceuticals Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 7, 2025 | Acquired by MannKind Corporation | — | Acquisition | Source |
Tools for this story
Each opens in a new tab, filled in for scPharmaceuticals Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.